BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1480 related articles for article (PubMed ID: 16174858)

  • 1. Estrogen-plus-progestin use and mammographic density in postmenopausal women: Women's Health Initiative randomized trial.
    McTiernan A; Martin CF; Peck JD; Aragaki AK; Chlebowski RT; Pisano ED; Wang CY; Brunner RL; Johnson KC; Manson JE; Lewis CE; Kotchen JM; Hulka BS;
    J Natl Cancer Inst; 2005 Sep; 97(18):1366-76. PubMed ID: 16174858
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prior hormone therapy and breast cancer risk in the Women's Health Initiative randomized trial of estrogen plus progestin.
    Anderson GL; Chlebowski RT; Rossouw JE; Rodabough RJ; McTiernan A; Margolis KL; Aggerwal A; David Curb J; Hendrix SL; Allan Hubbell F; Khandekar J; Lane DS; Lasser N; Lopez AM; Potter J; Ritenbaugh C
    Maturitas; 2006 Sep; 55(2):103-15. PubMed ID: 16815651
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Post-treatment change in serum estrone predicts mammographic percent density changes in women who received combination estrogen and progestin in the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial.
    Ursin G; Palla SL; Reboussin BA; Slone S; Wasilauskas C; Pike MC; Greendale GA
    J Clin Oncol; 2004 Jul; 22(14):2842-8. PubMed ID: 15254051
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of new-onset breast discomfort with an increase in mammographic density during hormone therapy.
    Crandall CJ; Karlamangla A; Huang MH; Ursin G; Guan M; Greendale GA
    Arch Intern Med; 2006 Aug 14-28; 166(15):1578-84. PubMed ID: 16908790
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estrogen plus progestin and the risk of coronary heart disease.
    Manson JE; Hsia J; Johnson KC; Rossouw JE; Assaf AR; Lasser NL; Trevisan M; Black HR; Heckbert SR; Detrano R; Strickland OL; Wong ND; Crouse JR; Stein E; Cushman M;
    N Engl J Med; 2003 Aug; 349(6):523-34. PubMed ID: 12904517
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mammographic Density Change With Estrogen and Progestin Therapy and Breast Cancer Risk.
    Byrne C; Ursin G; Martin CF; Peck JD; Cole EB; Zeng D; Kim E; Yaffe MD; Boyd NF; Heiss G; McTiernan A; Chlebowski RT; Lane DS; Manson JE; Wactawski-Wende J; Pisano ED
    J Natl Cancer Inst; 2017 Sep; 109(9):. PubMed ID: 28376149
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Menopausal symptoms and treatment-related effects of estrogen and progestin in the Women's Health Initiative.
    Barnabei VM; Cochrane BB; Aragaki AK; Nygaard I; Williams RS; McGovern PG; Young RL; Wells EC; O'Sullivan MJ; Chen B; Schenken R; Johnson SR;
    Obstet Gynecol; 2005 May; 105(5 Pt 1):1063-73. PubMed ID: 15863546
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of estrogen plus progestin on knee symptoms and related disability in postmenopausal women: The Heart and Estrogen/Progestin Replacement Study, a randomized, double-blind, placebo-controlled trial.
    Nevitt MC; Felson DT; Williams EN; Grady D
    Arthritis Rheum; 2001 Apr; 44(4):811-8. PubMed ID: 11315920
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Estrogen plus progestin and colorectal cancer in postmenopausal women.
    Chlebowski RT; Wactawski-Wende J; Ritenbaugh C; Hubbell FA; Ascensao J; Rodabough RJ; Rosenberg CA; Taylor VM; Harris R; Chen C; Adams-Campbell LL; White E;
    N Engl J Med; 2004 Mar; 350(10):991-1004. PubMed ID: 14999111
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of estrogen-progestin and estrogen on mammographic density.
    Kaewrudee S; Anuwutnavin S; Kanpittaya J; Soontrapa S; Sakondhavat C
    J Reprod Med; 2007 Jun; 52(6):513-20. PubMed ID: 17694969
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Postmenopausal hormone therapy and change in mammographic density.
    Greendale GA; Reboussin BA; Slone S; Wasilauskas C; Pike MC; Ursin G
    J Natl Cancer Inst; 2003 Jan; 95(1):30-7. PubMed ID: 12509398
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Estrogen plus progestin and the risk of peripheral arterial disease: the Women's Health Initiative.
    Hsia J; Criqui MH; Rodabough RJ; Langer RD; Resnick HE; Phillips LS; Allison M; Bonds DE; Masaki K; Caralis P; Kotchen JM;
    Circulation; 2004 Feb; 109(5):620-6. PubMed ID: 14769684
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of medroxyprogesterone acetate on estrogen-dependent risks and benefits--an attempt to interpret the Women's Health Initiative results.
    Kuhl H; Stevenson J
    Gynecol Endocrinol; 2006 Jun; 22(6):303-17. PubMed ID: 16785155
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Venous thrombosis and conjugated equine estrogen in women without a uterus.
    Curb JD; Prentice RL; Bray PF; Langer RD; Van Horn L; Barnabei VM; Bloch MJ; Cyr MG; Gass M; Lepine L; Rodabough RJ; Sidney S; Uwaifo GI; Rosendaal FR
    Arch Intern Med; 2006 Apr; 166(7):772-80. PubMed ID: 16606815
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of ultra-low-dose transdermal estradiol on breast density in postmenopausal women.
    Grady D; Vittinghoff E; Lin F; Hanes V; Ensrud K; Habel LA; Wallace R; Macer J; Cummings SR; Shepherd J
    Menopause; 2007; 14(3 Pt 1):391-6. PubMed ID: 17224859
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risks of estrogen plus progestin therapy: a sensitivity analysis of findings in the Women's Health Initiative randomized controlled trial.
    Shapiro S
    Climacteric; 2003 Dec; 6(4):302-10; discussion 310-3. PubMed ID: 15006251
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Continuous Combined Estrogen Plus Progestin and Endometrial Cancer: The Women's Health Initiative Randomized Trial.
    Chlebowski RT; Anderson GL; Sarto GE; Haque R; Runowicz CD; Aragaki AK; Thomson CA; Howard BV; Wactawski-Wende J; Chen C; Rohan TE; Simon MS; Reed SD; Manson JE
    J Natl Cancer Inst; 2016 Mar; 108(3):. PubMed ID: 26668177
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined postmenopausal hormone therapy and cardiovascular disease: toward resolving the discrepancy between observational studies and the Women's Health Initiative clinical trial.
    Prentice RL; Langer R; Stefanick ML; Howard BV; Pettinger M; Anderson G; Barad D; Curb JD; Kotchen J; Kuller L; Limacher M; Wactawski-Wende J;
    Am J Epidemiol; 2005 Sep; 162(5):404-14. PubMed ID: 16033876
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of estrogen plus progestin on global cognitive function in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial.
    Rapp SR; Espeland MA; Shumaker SA; Henderson VW; Brunner RL; Manson JE; Gass ML; Stefanick ML; Lane DS; Hays J; Johnson KC; Coker LH; Dailey M; Bowen D;
    JAMA; 2003 May; 289(20):2663-72. PubMed ID: 12771113
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of estrogen and estrogen-progestin on mammographic parenchymal density. Postmenopausal Estrogen/Progestin Interventions (PEPI) Investigators.
    Greendale GA; Reboussin BA; Sie A; Singh HR; Olson LK; Gatewood O; Bassett LW; Wasilauskas C; Bush T; Barrett-Connor E
    Ann Intern Med; 1999 Feb; 130(4 Pt 1):262-9. PubMed ID: 10068383
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 74.